pp-247 Tablets
Dossier type
CTD
Dossier status
Under development
Country of origin
Canada
GMP approvals
Canada
Comments
Indication: Cardiovascular disease (high-risk type 2 diabetes with CAD) / Clinical stage: Phase 3 / Modality: Small molecule BET inhibitor / Mechanism & Target: Bromodomain and extra-terminal (BET) protein inhibition, specifically BRD4 BD2 selectivity / Route & form: Oral / Differentiation: First-in-class selective BET inhibitor for cardiovascular outcomes; reduces heart failure hospitalizations
Manufacturer #39446
| Clinical-stage biopharmaceutical company specializing in BET bromodomain epigenetic modulation. Completed Phase 3 cardiovascular program providing insights into epigenetic risk reduction mechanisms. Continues focused development targeting specific cardiovascular patient subpopulations. |
None